Bind Therapeutics Receives Stalking Horse Bid From Pfizer

Under the terms of this bid Pfizer has agreed to acquire all of binds assets for a total of $20 million in an all cash-type transaction. The company has been in a rough spot in terms of developing its Accurins platform.